1. Home
  2. CRSP vs SON Comparison

CRSP vs SON Comparison

Compare CRSP & SON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CRSP

CRISPR Therapeutics AG

N/A

Current Price

$55.44

Market Cap

5.8B

Sector

Health Care

ML Signal

N/A

Logo Sonoco Products Company

SON

Sonoco Products Company

N/A

Current Price

$48.50

Market Cap

5.4B

ML Signal

N/A

Company Overview

Basic Information
Metric
CRSP
SON
Founded
2013
1899
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Containers/Packaging
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
5.4B
IPO Year
2016
2014

Fundamental Metrics

Financial Performance
Metric
CRSP
SON
Price
$55.44
$48.50
Analyst Decision
Buy
Buy
Analyst Count
22
11
Target Price
★ $87.56
$62.89
AVG Volume (30 Days)
★ 1.3M
1.0M
Earning Date
11-09-2026
10-21-2026
Dividend Yield
N/A
★ 4.42%
EPS Growth
N/A
★ 510.30
EPS
N/A
★ 0.68
Revenue
$289,590,000.00
★ $7,518,753,000.00
Revenue This Year
$1,063.30
N/A
Revenue Next Year
$283.48
$1.94
P/E Ratio
★ N/A
$72.99
Revenue Growth
★ 9169.85
41.72
52 Week Low
$44.12
$38.65
52 Week High
$78.48
$60.67

Technical Indicators

Market Signals
Indicator
CRSP
SON
Relative Strength Index (RSI) 52.39 30.63
Support Level $50.56 $46.74
Resistance Level $60.04 $49.38
Average True Range (ATR) 2.83 1.05
MACD -0.03 0.15
Stochastic Oscillator 51.06 0.15

Price Performance

Historical Comparison
CRSP
SON

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About SON Sonoco Products Company

Sonoco Products Co is engaged in the manufacture and supply of consumer and industrial packaging products, offering paper, metal, and plastic packaging solutions across multiple end markets. The company has two reportable segments: Consumer Packaging and Industrial Paper Packaging. The Consumer Packaging segment provides rigid packaging solutions mainly for food, beverage, household, personal care, and pharmaceutical products, while the Industrial Paper Packaging segment produces paper-based packaging materials such as tubes, cores, and protective packaging, supported by paper mills and recycling operations, serving industrial and consumer markets. It generates the majority of its revenue from the Consumer Packaging segment.

Share on Social Networks: